Long-acting bronchodilators in combination with inhaled corticosteroids (ICS) are
recommended to decrease the risk of recurrent exacerbations in patients with Global …

Objective: Bronchodilator maintenance treatment improves pulmonary function and health-
related quality of life in COPD patients. Pulmonary function and patient …

OBJECTIVES: In light of recent results from observational studies showing prolonged
survival in subjects taking long-acting β2-agonists (LABA) and/or inhaled corticosteroids …

Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …

A volume of published evidence sustains the role of long-acting β2-agonists in the treatment
of stable COPD. 1–5 These agents not only induce prolonged bronchodilation, but also …

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
globally, and its prevalence is projected to continue to increase owing to trends in smoking …

Background Overuse of short-acting beta-agonists (SABA) is described in asthma, but little is
known about overuse of SABA in chronic obstructive pulmonary disease (COPD). Methods …

Objectives To investigate the determinants of patient withdrawal from our study, and the
effect of these withdrawals on the outcome of treatment with inhaled corticosteroids in …

Since chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
obstruction, inhaled bronchodilators form the mainstay of treatment. A variety of new inhaled …

Current evidence supports the recommendation of the Global Initiative for Chronic
Obstructive Lung Disease guidelines of at least one of the two classes of long-acting inhaled …